BACKGROUND: Major depressive disorders (MDD) present a significant public health problem, in terms of burden for individual sufferers, their families and society as a whole. Recently, dualacting antidepressants, which block both serotonin (5-HT) and noradrenaline (NA) reuptake, have been developed with the hope of improving depression treatment outcomes. Duloxetine is a dual reuptake inhibitor of 5-HT and NA that has recently been licensed in the USA for the treatment of MDD. OBJECTIVE: This...Expand abstract
- Publication status:
- Publisher copy:
- Copyright date:
Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression.
If you are the owner of this record, you can report an update to it here: Report update to this record